AtriCure (NASDAQ: ATRC) reported Q2 EPS of ($0.32), $0.03 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $84.5 million versus the consensus estimate of $79.67 million.

GUIDANCE:

AtriCure sees FY2022 EPS of ($1.07)-($1.12), versus the consensus of ($1.10). AtriCure sees FY2022 revenue of $323-333 million, versus the consensus of $324.43 million.

For earnings history and earnings-related data on AtriCure (ATRC) click here.